Monoclonal antibodies directed against tumor necrosis factor alpha (anti-TNF-α 
agents) have dramatically changed the therapeutical approach to inflammatory 
bowel diseases, such as Crohn's disease and ulcerative colitis. A new anti-TNF 
drug, golimumab, has recently been approved for patients with moderate to severe 
ulcerative colitis. Its efficacy has been demonstrated by preclinical and 
clinical studies and the drug showed an efficacy and safety profile in line with 
the other anti-TNF agents, such as infliximab and adalimumab. This review gives 
an overview on golimumab in the treatment of moderate to severe ulcerative 
colitis.